Skip to Content

Generic Micro-K Availability

See also: Generic Micro-K 10

Micro-K is a brand name of potassium chloride, approved by the FDA in the following formulation(s):

MICRO-K (potassium chloride - capsule, extended release;oral)

  • Manufacturer: NESHER PHARMS
    Approved Prior to Jan 1, 1982
    Strength(s): 8MEQ [RLD] [AB]

Has a generic version of Micro-K been approved?

Yes. The following products are equivalent to Micro-K:

KLOR-CON (potassium chloride capsule, extended release;oral)

  • Manufacturer: UPSHER SMITH LABS
    Approval date: July 10, 2015
    Strength(s): 8MEQ [AB]

potassium chloride capsule, extended release;oral

  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: June 2, 2008
    Strength(s): 8MEQ [AB]
  • Manufacturer: ADARE PHARMS INC
    Approval date: March 17, 2017
    Strength(s): 8MEQ [AB]
  • Manufacturer: ANCHEN PHARMS
    Approval date: December 26, 2013
    Strength(s): 8MEQ [AB]
  • Manufacturer: LANNETT CO INC
    Approval date: March 28, 2016
    Strength(s): 8MEQ [AB]
  • Manufacturer: LUPIN LTD
    Approval date: December 18, 2015
    Strength(s): 8MEQ [AB]
  • Manufacturer: NOVEL LABS INC
    Approval date: August 16, 2016
    Strength(s): 8MEQ [AB]
  • Manufacturer: PADDOCK LLC
    Approval date: May 18, 2011
    Strength(s): 8MEQ [AB]
  • Manufacturer: PII
    Approval date: December 8, 2015
    Strength(s): 8MEQ [AB]
  • Manufacturer: PRINSTON INC
    Approval date: June 11, 2019
    Strength(s): 8MEQ [AB]
  • Manufacturer: TRIS PHARMA INC
    Approval date: March 4, 2016
    Strength(s): 8MEQ [AB]
  • Manufacturer: ZYDUS PHARMS
    Approval date: March 11, 2019
    Strength(s): 8MEQ [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Micro-K. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Micro-K (potassium chloride)

Consumer resources

Other brands: Klor-Con, K-Dur, K-Tab, Kaon-CI, Rum-K

Professional resources

Related treatment guides


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.